Verity Drug Patent Portfolio

Verity owns 2 orange book drugs protected by 15 US patents Given below is the list of Verity's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11464735 Fixed dose oral testosterone undecanoate compositions and use thereof 28 Apr, 2041
Active
US12011503 Fixed dose oral testosterone undecanoate compositions and use thereof 16 Oct, 2040
Active
US11559530 Oral testosterone undecanoate therapy 28 Nov, 2037
Active
US10226473 High-strength testosterone undecanoate compositions 30 Nov, 2030
Active
US10716794 High-strength testosterone undecanoate compositions 30 Nov, 2030
Active
US11311555 High-strength testosterone undecanoate compositions 30 Nov, 2030
Active
US11364249 High-strength testosterone undecanoate compositions 30 Nov, 2030
Active
US11433083 High-strength testosterone undecanoate compositions 30 Nov, 2030
Active
US9943527 High-strength testosterone undecanoate compositions 30 Nov, 2030
Active
US9949985 High-strength testosterone undecanoate compositions 30 Nov, 2030
Active
US10166181 Slow release pharmaceutical composition made of microgranules 30 Jun, 2029
Active
US11304960 Steroidal compositions 08 Jan, 2029
Active
US8778922 Steroidal compositions 08 Jan, 2029
Active
US8865695 Steroidal compositions 08 Jan, 2029
Active
US5776885 Sustained and controlled release of water insoluble polypeptides 07 Jul, 2015 Expired


Given below is the list of recent legal activities going on the following drug patents of Verity.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Yr, Small Entity 09 Mar, 2023 US10226473
Surcharge for late Payment, Small Entity 09 Mar, 2023 US10226473
Recordation of Patent Grant Mailed 24 Jan, 2023 US11559530
Patent Issue Date Used in PTA Calculation 24 Jan, 2023 US11559530
Correspondence Address Change 09 Jan, 2023 US11464735
Email Notification 05 Jan, 2023 US11559530
Issue Notification Mailed 04 Jan, 2023 US11559530
Mail Miscellaneous Communication to Applicant 28 Dec, 2022 US11559530
Email Notification 28 Dec, 2022 US11559530
Miscellaneous Communication to Applicant - No Action Count 22 Dec, 2022 US11559530
Application Is Considered Ready for Issue 21 Dec, 2022 US11559530
Dispatch to FDC 21 Dec, 2022 US11559530
Request for Refund 19 Dec, 2022 US11559530
Email Notification 16 Dec, 2022 US11559530
Change in Power of Attorney (May Include Associate POA) 16 Dec, 2022 US11559530


Verity Drug Patents' Oppositions Filed in EPO

Verity drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 13, 2017, by Generics (Uk) Ltd. This opposition was filed on patent number EP08763237A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP12172232A Apr, 2019 Generics [UK] Ltd Granted and Under Opposition
EP08763237A Sep, 2017 Ferring B.V. Revoked
EP08763237A Sep, 2017 Generics (UK) Ltd Revoked


Verity's Family Patents

Verity drugs have patent protection in a total of 36 countries. It's US patent count contributes only to 47.5% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Verity Drug List

Given below is the complete list of Verity's drugs and the patents protecting them.


1. Tlando

Tlando is protected by 13 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11464735 Fixed dose oral testosterone undecanoate compositions and use thereof 28 Apr, 2041
(16 years from now)
Active
US12011503 Fixed dose oral testosterone undecanoate compositions and use thereof 16 Oct, 2040
(16 years from now)
Active
US11559530 Oral testosterone undecanoate therapy 28 Nov, 2037
(13 years from now)
Active
US10226473 High-strength testosterone undecanoate compositions 30 Nov, 2030
(6 years from now)
Active
US10716794 High-strength testosterone undecanoate compositions 30 Nov, 2030
(6 years from now)
Active
US11311555 High-strength testosterone undecanoate compositions 30 Nov, 2030
(6 years from now)
Active
US11364249 High-strength testosterone undecanoate compositions 30 Nov, 2030
(6 years from now)
Active
US11433083 High-strength testosterone undecanoate compositions 30 Nov, 2030
(6 years from now)
Active
US9943527 High-strength testosterone undecanoate compositions 30 Nov, 2030
(6 years from now)
Active
US9949985 High-strength testosterone undecanoate compositions 30 Nov, 2030
(6 years from now)
Active
US11304960 Steroidal compositions 08 Jan, 2029
(4 years from now)
Active
US8778922 Steroidal compositions 08 Jan, 2029
(4 years from now)
Active
US8865695 Steroidal compositions 08 Jan, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tlando's drug page


2. Trelstar

Trelstar is protected by 2 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10166181 Slow release pharmaceutical composition made of microgranules 30 Jun, 2029
(4 years from now)
Active
US5776885 Sustained and controlled release of water insoluble polypeptides 07 Jul, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trelstar's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List